ALXO ALXO
Company Profile ↓Company Overview
ALXO (ALXO) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +227.09% |
| 6 Months: | +2.67% |
| 3 Months: | -0.52% |
| 1 Month: | -18.64% |
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)46.42 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 26.1% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 1.29M | 1.26M | 655.00K | 527.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -4.19M | -3.03M | -5.24M | -10.79M | -9.81M | -14.21M | -16.30M | -24.58M | -24.75M | -33.79M | -36.68M | -32.20M | -36.78M | -53.27M | -37.76M | -41.52M | -32.57M | -31.82M | -26.65M | -22.53M | -18.97M |
| Net Income | -4.24M | -4.20M | -3.04M | -5.45M | -11.33M | -10.18M | -14.19M | -16.27M | -24.57M | -24.53M | -32.92M | -35.32M | -30.18M | -34.16M | -50.99M | -35.58M | -39.40M | -30.71M | -30.75M | -25.95M | -22.14M | -17.93M |
| Diluted EPS | - | - | - | - | - | - | - | -0.40 | -0.61 | -0.60 | -0.81 | -0.87 | -0.74 | -0.84 | -1.24 | -0.71 | -0.76 | -0.58 | -0.58 | -0.49 | -0.41 | -0.17 |
| R&D Expense | - | 3.63M | 2.21M | 3.83M | 7.66M | 5.33M | 9.85M | 11.21M | 18.21M | 17.07M | 26.75M | 29.38M | 24.76M | 29.48M | 45.77M | 31.72M | 34.65M | 26.47M | 23.89M | 18.02M | 17.44M | 13.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2.07M | 4.80M | 1.18M | 0 | 0 | - | - | - |
| Operating Income | -13.68M | -19.18M | -43.66M | -83.56M | -127.44M | -170.28M | -142.47M | -104.02M |
| Net Income | -13.73M | -19.24M | -45.74M | -83.46M | -123.48M | -160.81M | -134.85M | -101.69M |
| Diluted EPS | - | - | -2.76 | -2.07 | -3.03 | -3.74 | -2.58 | -1.90 |
| R&D Expense | 11.27M | 16.31M | 28.96M | 60.17M | 98.40M | 141.79M | 116.37M | 77.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 10.68M | 436.05M | 380.18M | 306.49M | 242.55M | 147.78M | 59.05M |
| Total Equity | -38.41M | -51.78M | -70.64M | 429.85M | 363.05M | 263.46M | 189.71M | 113.62M | 25.98M |
| Cash & Equivalents | - | - | 9.02M | 434.22M | 363.67M | 48.82M | 22.41M | 17.57M | 16.37M |
| Long Term Debt | - | - | 5.42M | - | - | 9.39M | 9.64M | 9.47M | 4.53M |
| Total Liabilities | - | - | 10.95M | 6.21M | 17.13M | 43.02M | 52.84M | 34.16M | 33.06M |
| Current Liabilities | - | - | 4.98M | 6.20M | 15.29M | 28.32M | 36.00M | 18.50M | 24.55M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -13.19M | -14.25M | -38.29M | -68.10M | -89.22M | -130.36M | -121.91M | -84.14M |
| Investing Cash Flow | -653.00K | -353.00K | 610.00K | -4.92M | -235.42M | 44.66M | 86.26M | 82.59M |
| Financing Cash Flow | 1.00K | 15.36M | 462.88M | 2.47M | 9.86M | 59.29M | 30.82M | 362.00K |
| Capital Expenditure | -653.00K | -353.00K | -31.00K | -666.00K | -1.43M | -1.27M | -447.00K | -212.00K |
| Free Cash Flow | -13.84M | -14.60M | -38.32M | -68.77M | -90.65M | -131.64M | -122.36M | -84.35M |
| Share Buybacks | 6.00K | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | -662.0% | -400.0% | -3,694.0% | - | - | - | - | - |
| Net Margin % | -664.3% | -401.2% | -3,869.7% | - | - | - | - | - |
| ROE % | 26.5% | 27.2% | -10.6% | -23.0% | -46.9% | -84.8% | -118.7% | -391.4% |
| ROCE % | - | -337.0% | -10.2% | -22.9% | -45.8% | -82.4% | -110.2% | -301.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALXO
BlackRock, Inc. Expands Stake in ALX Oncology Holdings Inc (ALXO) with Strategic Share Purchase - GuruFocus
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQYW1ENzJzVEJ3cVlmOWhrYkdpekowcUp1X3J0NDFWS3paXzY1bEpuZ280OWZWQ2hTZ2wyQmhsOFh2WXlUWjh0TXdhcE5KY1ZwNG9SV1ZkRnlEN1lFdUVKOUZxMnJjZ01ZZDFZWXZQR2xHVkFFSHlSWG03WmdVc2t6UXdwUW43Z2hTS3hVQ1…
ALXO Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9vdFJTYlRWdEJ4VUpOSDlHOFBHdkl5U25mQXRNXzE1Yk5kWm5oY1FfVlZCcXZkdktpeElmQTBqdXM1Q0ZvMXRKcDdvdEZXeHM5RkxHaXdmb05fNEphcHpkS2JMMENsYWVLWjl1MjRybjd0NWxvVDFxYlFn?oc=5" target="_blank">ALX…
$ALXO stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQQ1dMZ2hBUDZJYXVqbmRtXzljWFFBQjlwcUdVV2lBOXNLUGw5NF9zWGxhMUVRYWJGMXlVZ2JHUHdCY1h0TmlhNnFLR2ZmZklOa3FWOWgtQ2tsVjl1dGhxSC1keUhxemF0MlpmMGpwM1E3WnBDMDJyZEJEMUlEVDBRcGRUVmN6RmsyWm1WWT…
BlackRock (NYSE: BLK) reports 5.4% passive stake in ALX Oncology (ALXO) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxQTmpMN3ZhMDVsV1dZNzhxOEhnazk3VWhNQWY4RzB5QWRWQmtRYmw5TDZyaUwyaFk5c3hPUjY5WGNaTTVhOTFvVnc4UTk2bm84YzNhYVJVQmxzS0dhODBoLW8tMTZxVE5kVHh3cmdxVXc5UWttekxfTVNFWmFndi04OGdZUEF6MnVoWmJiWE…
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQdk9CcHA2Sk9GemZFUl94bUpzZUUyRnZhcDNtSkVHeGlSdFRESEpSeXJiYWNneXM3cnlMUlFKekZ2QXl4NEY1Ynh6ZFRNY2lXOUdHdE5LWExQWEctV3pqY0hqVUMxUU1uUENhWTBUb2xrczVqMU9SSDR6SE5YNS1oelNQRFF2RTJXd1hCVE…
Insider Returns Down To US$122k As ALX Oncology Holdings' Stock Dips 15% - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6wFBVV95cUxNZm1Wam00ZjEtNDM0VUZNNUF2dXhUQklxcTY1WDlsVGxPcTFqTzg0TXp4UjdvMDA1UHJJN2tGc29xYlBPclQtUGVlM0lySU1SV2FFdzNrOWdoOWlNTjFiSEd0ZHFIdklVVFRMX2tDX2RpbWUzelU3b3ozWHdJSkRwTGkyRUZqd0dPQ2YteE…
ALXO — Frequently Asked Questions
What is the current share price of ALXO?
As of 2026-08-05 17:25 PDT, ALXO trades at $1.92 on NASDAQ/NYSE. Its 52-week range is $0.59 to $2.60.
What is the P/E ratio of ALXO?
ALXO trades at a trailing price-to-earnings (P/E) ratio of -1.01.
Is ALXO a good stock to buy?
This page provides a data-driven analysis of ALXO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.